Temazepam: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Temazepam. Educational only — not medical advice.
Reported adverse reactions
| Reaction | Highest frequency reported* |
|---|---|
| Drowsiness | 9.1% |
| Headache | 9.1% |
| Nervousness | 8.2% |
| Fatigue | 4.8% |
| Lethargy | 4.5% |
| Dizziness | 4.5% |
| Nausea | 3.8% |
| Hangover | 2.5% |
| Dry mouth | 2.2% |
| Anxiety | 2% |
| Abdominal discomfort | 1.9% |
| Depression | 1.8% |
| Diarrhea | 1.7% |
| Nightmares | 1.7% |
| Euphoria | 1.5% |
| Weakness | 1.4% |
| Confusion | 1.3% |
| Blurred vision | 1.3% |
| Vertigo | 1.2% |
*Highest percentage across placebo-controlled trial tables summarized in current labeling.
Labeled uses
Temazepam capsules are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment.
Source: FDA labeling via NIH DailyMed (set 6248295e…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.